HIF1α is required for NK cell metabolic adaptation during virus infection

  1. Francisco Victorino  Is a corresponding author
  2. Tarin Bigley
  3. Eugene Park
  4. Cong-Hui Yao
  5. Jeanne Benoit
  6. Liping Yang
  7. Sytse J Piersma
  8. Elvin J Lauron
  9. Rebecca M Davidson
  10. Gary Patti
  11. Wayne M Yokoyama  Is a corresponding author
  1. Washington University School of Medicine, United States
  2. Washington University, United States
  3. National Jewish Health, United States
  4. University of Iowa, United States

Abstract

Natural killer (NK) cells are essential for early protection against virus infection, and must metabolically adapt to the energy demands of activation. Here, we found upregulation of the metabolic adaptor hypoxia inducible factor-1α (HIF-1α) is a feature of mouse NK cells during murine cytomegalovirus (MCMV) infection in vivo. HIF-1 α -deficient NK cells failed to control viral load, causing increased morbidity. No defects were found in effector functions of HIF-1α KO NK cells however, their numbers were significantly reduced. Loss of HIF-1 α did not affect NK cell proliferation during in vivo infection and in vitro cytokine stimulation. Instead, we found HIF-1α -deficient NK cells showed increased expression of the pro-apoptotic protein Bim and glucose metabolism was impaired during cytokine stimulation in vitro. Similarly, during MCMV infection HIF-1α -deficient NK cells upregulated Bim and had increased caspase activity. Thus, NK cells require HIF-1α-dependent metabolic functions to repress Bim expression and sustain cell numbers for an optimal virus response.

Data availability

Data generated or analyzed during this study has been deposited to the Dryad Digital Depository, available here: doi:10.5061/dryad.n5tb2rbvm

The following data sets were generated

Article and author information

Author details

  1. Francisco Victorino

    Rheumatology Division, Washington University School of Medicine, St. Louis, United States
    For correspondence
    ramirezvictorino@wustl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7626-3219
  2. Tarin Bigley

    Rheumatology Division, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Eugene Park

    Rheumatology Division, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2617-7571
  4. Cong-Hui Yao

    Department of Chemistry, Department of Medicine, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Jeanne Benoit

    Department of Biomedical Research, Center for Genes, Environment and Health, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Liping Yang

    Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Sytse J Piersma

    Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5379-3556
  8. Elvin J Lauron

    Rheumatology Division, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Rebecca M Davidson

    Department of Biomedical Research, Center for Genes, Environment and Health, National Jewish Health, Denver, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Gary Patti

    FOEDRC Metabolomics Core Facility, University of Iowa, Iowa City, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3748-6193
  11. Wayne M Yokoyama

    Department of Medicine, Washington University School of Medicine, St Louis, United States
    For correspondence
    yokoyama@wustl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0566-7264

Funding

National Institute of Environmental Health Sciences (R35ES028365)

  • Gary Patti

National Institute of Allergy and Infectious Diseases (R01-AI131680)

  • Wayne M Yokoyama

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#20180293) of the University of Washington in St. Louis School of Medicine.

Copyright

© 2021, Victorino et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,164
    views
  • 335
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Francisco Victorino
  2. Tarin Bigley
  3. Eugene Park
  4. Cong-Hui Yao
  5. Jeanne Benoit
  6. Liping Yang
  7. Sytse J Piersma
  8. Elvin J Lauron
  9. Rebecca M Davidson
  10. Gary Patti
  11. Wayne M Yokoyama
(2021)
HIF1α is required for NK cell metabolic adaptation during virus infection
eLife 10:e68484.
https://doi.org/10.7554/eLife.68484

Share this article

https://doi.org/10.7554/eLife.68484

Further reading

    1. Immunology and Inflammation
    Yan Qian, Qiannv Liu ... Pengyan Xia
    Research Article

    The T6SS of Pseudomonas aeruginosa plays an essential role in the establishment of chronic infections. Inflammasome-mediated inflammatory cytokines are crucial for host defense against bacterial infections. We found that P. aeruginosa infection activates the non-canonical inflammasome in macrophages, yet it inhibits the downstream activation of the NLRP3 inflammasome. The VgrG2b of P. aeruginosa is recognized and cleaved by caspase-11, generating a free C-terminal fragment. The VgrG2b C-terminus can bind to NLRP3, inhibiting the activation of the NLRP3 inflammasome by rejecting NEK7 binding to NLRP3. Administration of a specific peptide that inhibits caspase-11 cleavage of VgrG2b significantly improves mouse survival during infection. Our discovery elucidates a mechanism by which P. aeruginosa inhibits host immune response, providing a new approach for the future clinical treatment of P. aeruginosa infections.

    1. Immunology and Inflammation
    2. Medicine
    Ole Bæk, Tik Muk ... Duc Ninh Nguyen
    Research Article

    Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity, organ damage, and altered metabolism following infection. Given the unique metabolic challenges and poor glucose regulatory capacity of preterm infants, their glucose intake during infection may have a high impact on the degree of metabolism dysregulation and organ damage. Using a preterm pig model of neonatal sepsis, we previously showed that a drastic restriction in glucose supply during infection protects against sepsis via suppression of glycolysis-induced inflammation, but results in severe hypoglycemia. Now we explored clinically relevant options for reducing glucose intake to decrease sepsis risk, without causing hypoglycemia and further explore the involvement of the liver in these protective effects. We found that a reduced glucose regime during infection increased survival via reduced pro-inflammatory response, while maintaining normoglycemia. Mechanistically, this intervention enhanced hepatic oxidative phosphorylation and possibly gluconeogenesis, and dampened both circulating and hepatic inflammation. However, switching from a high to a reduced glucose supply after the debut of clinical symptoms did not prevent sepsis, suggesting metabolic conditions at the start of infection are key in driving the outcome. Finally, an early therapy with purified human inter-alpha inhibitor protein, a liver-derived anti-inflammatory protein, partially reversed the effects of low parenteral glucose provision, likely by inhibiting neutrophil functions that mediate pathogen clearance. Our findings suggest a clinically relevant regime of reduced glucose supply for infected preterm infants could prevent or delay the development of sepsis in vulnerable neonates.